About US
Contact us
-
Novo CEO scolds European officials for 'empty promises' on new drugsNovo Nordisk ($NVO) CEO Lars Sørensen says Europe needs to loosen its purse strings to keep drug innovation coming. If austerity-minded governments aren't willing to pay for new drugs, then hi2013/5/17
-
Jury is out in another case linking Novartis' Zometa to jawbone deathNovartis ($NVS) is one step closer to knowing how its latest round of Zometa litigation works out. After 11 days of testimony, the jury has started deliberating its verdict on plaintiff Beverly Meng'2013/5/16
-
Bayer's radiotherapy Xofigo wins FDA nod in prostate cancerThe FDA has hit the green light for Xofigo--initially calledAlpharadinor radium-223 chloride--for castration-resistantprostate cancer. The approval demonstrates the agency's growing comfort with targ2013/5/16
-
Fast cost-cutting puts Merck KGaA a year ahead on financial targetsMerck KGaA is a year ahead of schedule. The German drugmaker, which has been slashing payrolls and shutting facilties to save money, said it would meet its 2014 sales and earnings targets this year i2013/5/15
-
Congressional Repubs challenge FDA on deputy commissioner's exitA revolving door inside the FDA has captured the attention of a group of Republican lawmakers. Just a few months after Leona Brenner-Gati was named Acting Deputy Commissioner for Medical Products and2013/5/15
-
Astellas forecasts big sales growth as prostate drug catches holdJapan's drugmakers aren't any more immune togeneric competition than U.S. pharma companies are. Still, the country's second- and third-largest drugmakers are predicting sales growth this year, even a2013/5/14
-
Biological data warehouses helps speed up drug development, researchers sayDrawing on patient information from a biological data warehouse has the potential to speed up drug development and cut costs, according to researchers from the Moffitt Cancer Center in the US.The team2013/5/14
-
FDA gives Novartis' Ilaris big boost with nod for rare juvenile arthritisNovartis ($NVS) has grabbed one of two new indications it was shooting for with its rare disease drug Ilaris, one step toward turning the drug into a blockbuster. The FDA approved Ilaris for treatm2013/5/13
-
CFDA specifies relevant issues on written confirmation for active substances exported to EUChina Food and Drug Administration (CFDA) recently issued a notice on relevant issues on written confirmation for active substances exported to EU, which specifies the issuer, the issuance method, and2013/5/13
-
After going it alone, Vivus finally open to Big Pharma sales partnershipWhen Vivus ($VVUS) announced first-quarter earnings yesterday, sales weren't just off of analyst estimates. They also crushed investors' hopes that the company could halt its continued failure to get2013/5/10